Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 26

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 26
---
 this proposal, when designing our compensation programs and making future compensation decisions for our named executive officers. Abstentions and broker non-votes, if any, will not have any effect on the results of those deliberations. Unless the Board determines otherwise, the next “say-on-pay” advisory vote will be held at the 2026 annual meeting of stockholders.

The Board recommends that stockholders vote “FOR” the compensation of our named executive officers for 2024.

<div align='center'>THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

15</div>

VOTE TO APPROVE AN AMENDMENT TO THE 2018 PLAN (Proposal 3) Proposal The Company and the Board have proposed to amend the Company’s 2018 Equity Incentive Plan (as amended on April 3, 2020, April 5, 2022 and April 6, 2023) (the “2018 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 4,300,000 shares to 17,487,596 shares (plus the number of shares subject to outstanding awards under the Amended and Restated 2011 Equity Incentive Plan (the “2011 Plan”) that expire or otherwise terminate without having been exercised in full, or are forfeited to or repurchased by us up to a maximum as described below). Purpose and Effect of the Proposal The Board believes that long-term equity awards are an extremely important way to attract, motivate and retain key employees, including a talented executive team, and align the employees’ and executives’ interests with those of the Company’s stockholders. The Board also believes that long-term equity compensation is essential to link executive compensation with long-term stockholder value creation. Equity compensation represents a significant portion of the compensation package for our key employees. Since our equity awards generally vest over several years, the value ultimately realized from these awards depends on the long-term value of our common stock. In addition, we use the 2018 Plan to grant performance-based restricted stock units ("PSUs") with vesting tied both to value-creating Company goals and objectives designed to incentivize the performance of our employees, including our named executive officers. We believe that granting equity awards motivates employees to think and act like owners, rewarding them when value is created for stockholders. In this proxy statement, we refer to any grant from the 2018 Plan as an “Award